Keros Therapeutics, Inc. (KROS) Stock Score, Valuation & Financial Research
Keros Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 66/100.
Quick answer for KROS
Keros Therapeutics, Inc. currently has a Wall Street Score of 66/100. The stored market price is $11.17. Its financial score is 50/100. Its valuation score is 100/100. These figures are a research snapshot, not a buy or sell recommendation.
What Keros Therapeutics, Inc. does
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the fir
KROS financial snapshot
- Wall Street Score:
- 66/100
- Current price:
- $11.17
- Market capitalization:
- $357.4M
- Revenue:
- $33.2M
- Net income:
- $-85.1M
- Free cash flow:
- $106.0M
- Cash:
- $281.5M
- Total debt:
- $16.3M
- EPS:
- 2.34
- P/E ratio:
- 4.8x
- Financial score:
- 50/100
- Valuation score:
- 100/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.9%.
- Free cash flow is $106.0M, showing positive cash generation.
- The balance sheet shows $281.5M of cash versus $16.3M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research KROS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.